BEX1 and hepatocellular carcinoma: These results indicate that BEX1 is a promising therapeutic target forHB and CSC-HCC, and targeting the BeX1-mediated Wnt/β-catenin signaling pathway may help to resolve the heterogeneity and high recurrence rate of HCC.